N. Iscoe

767 total citations
26 papers, 594 citations indexed

About

N. Iscoe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, N. Iscoe has authored 26 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in N. Iscoe's work include Prostate Cancer Diagnosis and Treatment (5 papers), Lung Cancer Research Studies (4 papers) and Prostate Cancer Treatment and Research (4 papers). N. Iscoe is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (5 papers), Lung Cancer Research Studies (4 papers) and Prostate Cancer Treatment and Research (4 papers). N. Iscoe collaborates with scholars based in Canada, United States and United Kingdom. N. Iscoe's co-authors include Vivek Goel, Ian Quirt, Eric J. Holowaty, C. David Naylor, Gordon Fehringer, Kejin Wu, Isra Levy, James J. Rusthoven, A. Bodurtha and David Osoba and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

N. Iscoe

25 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Iscoe Canada 14 358 170 131 112 61 26 594
Zhuoqiao Wang United States 10 251 0.7× 185 1.1× 155 1.2× 118 1.1× 36 0.6× 17 625
Guifang Guo China 15 353 1.0× 123 0.7× 86 0.7× 117 1.0× 44 0.7× 36 632
David Hrouda United Kingdom 15 144 0.4× 303 1.8× 138 1.1× 241 2.2× 62 1.0× 43 640
Mehmet Akif Öztürk Türkiye 12 295 0.8× 147 0.9× 151 1.2× 123 1.1× 49 0.8× 40 642
Xiaoling Niu China 13 309 0.9× 106 0.6× 72 0.5× 69 0.6× 29 0.5× 44 646
Jason C. Barnett United States 18 211 0.6× 79 0.5× 136 1.0× 268 2.4× 78 1.3× 33 911
Joshua P. Kesterson United States 18 235 0.7× 86 0.5× 190 1.5× 129 1.2× 64 1.0× 60 779
Liyan Liu China 14 188 0.5× 144 0.8× 131 1.0× 93 0.8× 59 1.0× 31 660
Gina Villani United States 10 214 0.6× 133 0.8× 67 0.5× 49 0.4× 49 0.8× 24 456
E. Greer Gay United States 7 247 0.7× 322 1.9× 109 0.8× 179 1.6× 27 0.4× 10 680

Countries citing papers authored by N. Iscoe

Since Specialization
Citations

This map shows the geographic impact of N. Iscoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Iscoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Iscoe more than expected).

Fields of papers citing papers by N. Iscoe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Iscoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Iscoe. The network helps show where N. Iscoe may publish in the future.

Co-authorship network of co-authors of N. Iscoe

This figure shows the co-authorship network connecting the top 25 collaborators of N. Iscoe. A scholar is included among the top collaborators of N. Iscoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Iscoe. N. Iscoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, David, Víctor Rodríguez-Freixinós, Mark Doherty, et al.. (2022). Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. European Journal of Cancer. 169. 74–81. 22 indexed citations
2.
Cullen, M.H., Petr Zatloukal, S Sörenson, et al.. (2008). A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 19(5). 939–945. 64 indexed citations
3.
Brade, Anthony, Andrea Bezjak, Robert M. MacRae, et al.. (2007). Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study. International Journal of Radiation Oncology*Biology*Physics. 69(3). S490–S490. 1 indexed citations
4.
Zatloukal, Petr, S Sörenson, Silvia Novello, et al.. (2007). Pemetrexed in advanced non-small cell lung cancer: A randomized trial of 500 mg/m2 vs 900 mg/m2 in 588 patients who progressed after platinum-containing chemotherapy. Journal of Clinical Oncology. 25(18_suppl). LBA7727–LBA7727. 3 indexed citations
5.
Choo, Richard, Gillian Thomas, Tony Woo, et al.. (2005). Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. International Journal of Radiation Oncology*Biology*Physics. 61(3). 736–740. 53 indexed citations
6.
Winquist, Eric, et al.. (2004). A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer.. PubMed. 11(6). 2445–9. 4 indexed citations
7.
Hemels, Martin E W, Michaël Iskedjian, N. Iscoe, Neil Fleshner, & TR Einarson. (2002). CN2 COST-UTILITY ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER. Value in Health. 5(3). 129–130. 1 indexed citations
8.
Bunting, Peter S., et al.. (1999). Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.. PubMed. 160(1). 70–5. 28 indexed citations
9.
Mercer, Shawna L., Vivek Goel, Isra Levy, et al.. (1998). Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions.. PubMed. 88(5). 327–32. 33 indexed citations
10.
Levy, Isra, N. Iscoe, & Laurence Klotz. (1998). Prostate cancer: 1. The descriptive epidemiology in Canada.. PubMed. 159(5). 509–13. 17 indexed citations
11.
Lavis, John N., José María García de Lomas Guerrero, G. M. Anderson, et al.. (1998). Free-standing health care facilities: financial arrangements, quality assurance and a pilot study.. PubMed. 158(3). 359–63. 2 indexed citations
12.
13.
Iscoe, N., et al.. (1995). Orchidectomy and hormonal therapy of prostate cancer.. PubMed. 2(1). 109–15. 3 indexed citations
14.
Osoba, David, et al.. (1995). Predicting psychological distress in patients with cancer: conceptual basis and reliability evaluation of a self-report questionnaire.. PubMed. 15(4). 1533–42. 11 indexed citations
15.
Iscoe, N., et al.. (1994). Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference?. PubMed. 150(7). 1109–15. 18 indexed citations
16.
Verma, Sunil, Ian Quirt, E. Eisenhauer, et al.. (1993). A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma. Annals of Oncology. 4(3). 254–255. 7 indexed citations
17.
Shepherd, Frances A., Lorne Rotstein, Martin E. Blackstein, et al.. (1990). Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin. 3(4). 197–201. 1 indexed citations
18.
DeAngelis, Carlo, James J. Rusthoven, Ian G. Kerr, et al.. (1987). Re-evaluating the cost of outpatient cancer chemotherapy.. PubMed. 137(10). 903–6. 15 indexed citations
19.
Iscoe, N., et al.. (1985). The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. British journal of surgery. 72(8). 614–617. 30 indexed citations
20.
Shelley, W, Ian Quirt, A. Bodurtha, et al.. (1985). Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.. PubMed. 69(9). 941–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhuoqiao Wang Breakdown of academic impact, for papers by Guifang Guo Breakdown of academic impact, for papers by David Hrouda Breakdown of academic impact, for papers by Mehmet Akif Öztürk Breakdown of academic impact, for papers by Xiaoling Niu Breakdown of academic impact, for papers by Jason C. Barnett Breakdown of academic impact, for papers by Joshua P. Kesterson Breakdown of academic impact, for papers by Liyan Liu Breakdown of academic impact, for papers by Gina Villani Breakdown of academic impact, for papers by E. Greer Gay
Rankless by CCL
2026